Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Medically reviewed by Leah Ansell, MDMedically reviewed by Leah Ansell, MD Plaque psoriasis is the most common ... body but ...

scalp, and groin, but it can also be in the underarms, on your nails, or under the breasts. It can be anywhere.” And beyond the physical symptoms, plaque psoriasis also frequently has negative ...

The study was conducted among patients with plaque psoriasis affecting special areas such as the scalp, genitals and/or hands ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

Affecting more than 125 million people worldwide, plaque psoriasis is an immune-mediated disease characterised by inflamed, scaly plaques that may be itchy or painful. Sensitive or highly visible ...

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

Icotrokinra, formerly known as JNJ-2113, is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of moderate to severe ...

moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment. Data from the Phase 3b SPECTREM study to measure skin clearance and other treatment outcomes in low ...